Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It utilizes Logica, a platform offering from Valo Health, to identify advanceable small molecule leads. It provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Charles River Laboratories International Inc.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Privia Health Group (PRVA) and Charles River Labs (C...

Wall Street Analysts Are Bullish on Top Healthcare Picks

In a report released on May 8, Gregory Pardy from RBC Capital maintained a Buy rating on Cardinal Energy, with a price target of C$14.00. The compa...

RBC Capital Sticks to Its Buy Rating for Cardinal Energy (CJ)

Charles River Laboratories Intl (CRL) has disclosed a new risk, in the Cyber Security category. Charles River Laboratories Intl is exposed to growi...

Cyber Threats Loom Over Charles River Laboratories: Rising AI-Enabled Attacks, Third-Party Risks, and Potential Financial Fallout

Barclays analyst Luke Sergott maintained a Buy rating on Charles River Labs today and set a price target of $220.00. According to TipRanks, Sergott...

Current Quarter	$2.73	Next Quarter	$2.99
Current Year	$11.05	Next Year	$12
QoQ Growth	+9.5%	YoY Growth	+8.6%
3Y EPS CAGR	-100.0%	Target Price	$216.43
Consensus	Buy	Upside	+38.1%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CRL	$156.73	-2.23%	1.12M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CRL	$156.73	-2.2%	1.12M
3
4
5
6

CRL

CRL

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Charles River Laboratories International Inc. Data in Excel

Get Charles River Laboratories International Inc. Data in Excel